{
  "address1": "777 Old Saw Mill River Road",
  "city": "Tarrytown",
  "state": "NY",
  "zip": "10591-6707",
  "country": "United States",
  "phone": "914 847 7000",
  "website": "https://www.regeneron.com",
  "industry": "Biotechnology",
  "industryDisp": "Biotechnology",
  "sector": "Healthcare",
  "sectorDisp": "Healthcare",
  "longBusinessSummary": "Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.",
  "fullTimeEmployees": 12256,
  "companyOfficers": [
    {
      "maxAge": 1,
      "name": "Dr. Leonard S. Schleifer M.D., Ph.D.",
      "age": 69,
      "title": "Co-Founder, Pres, CEO & Co-Chairman",
      "yearBorn": 1953,
      "fiscalYear": 2022,
      "totalPay": 7004069,
      "exercisedValue": 0,
      "unexercisedValue": 256815824
    },
    {
      "maxAge": 1,
      "name": "Dr. George D. Yancopoulos M.D., Ph.D.",
      "age": 62,
      "title": "Co-Founder, Pres, Chief Scientific Officer & Co-Chairman",
      "yearBorn": 1960,
      "fiscalYear": 2022,
      "totalPay": 6593696,
      "exercisedValue": 0,
      "unexercisedValue": 242710064
    },
    {
      "maxAge": 1,
      "name": "Mr. Robert E. Landry Jr.",
      "age": 58,
      "title": "Exec. VP of Fin. & CFO",
      "yearBorn": 1964,
      "fiscalYear": 2022,
      "totalPay": 1839460,
      "exercisedValue": 11097488,
      "unexercisedValue": 25114408
    },
    {
      "maxAge": 1,
      "name": "Dr. Andrew J. Murphy Ph.D.",
      "age": 63,
      "title": "Exec. VP of Research",
      "yearBorn": 1959,
      "fiscalYear": 2022,
      "totalPay": 1622950,
      "exercisedValue": 19388300,
      "unexercisedValue": 83458888
    },
    {
      "maxAge": 1,
      "name": "Mr. Daniel P. Van Plew",
      "age": 49,
      "title": "Exec. VP and GM of Industrial Operations & Product Supply",
      "yearBorn": 1973,
      "fiscalYear": 2022,
      "totalPay": 1954399,
      "exercisedValue": 45282380,
      "unexercisedValue": 24788798
    },
    {
      "maxAge": 1,
      "name": "Ms. Marion E. McCourt",
      "age": 62,
      "title": "Exec. VP of Commercial",
      "yearBorn": 1960,
      "fiscalYear": 2022,
      "totalPay": 1500262,
      "exercisedValue": 4246309,
      "unexercisedValue": 8790830
    },
    {
      "maxAge": 1,
      "name": "Ms. Patrice  Gilooly",
      "title": "Sr. VP of Quality Assurance & Operations",
      "exercisedValue": 0,
      "unexercisedValue": 0
    },
    {
      "maxAge": 1,
      "name": "Mr. Christopher R. Fenimore CPA",
      "age": 51,
      "title": "Sr. VP, Head of Accounting & Controller",
      "yearBorn": 1971,
      "exercisedValue": 0,
      "unexercisedValue": 0
    },
    {
      "maxAge": 1,
      "name": "Mr. Gerald  Underwood",
      "title": "Sr. VP of Technical Operations",
      "exercisedValue": 0,
      "unexercisedValue": 0
    },
    {
      "maxAge": 1,
      "name": "Mr. Bob  McCowan",
      "title": "Sr. VP of IT & Chief Information Officer",
      "exercisedValue": 0,
      "unexercisedValue": 0
    }
  ],
  "auditRisk": 9,
  "boardRisk": 10,
  "compensationRisk": 9,
  "shareHolderRightsRisk": 10,
  "overallRisk": 10,
  "governanceEpochDate": 1693526400,
  "compensationAsOfEpochDate": 1672444800,
  "maxAge": 86400,
  "priceHint": 2,
  "previousClose": 823.38,
  "open": 822.02,
  "dayLow": 818.5295,
  "dayHigh": 831.5,
  "regularMarketPreviousClose": 823.38,
  "regularMarketOpen": 822.02,
  "regularMarketDayLow": 818.5295,
  "regularMarketDayHigh": 831.5,
  "payoutRatio": 0.0,
  "beta": 0.185684,
  "trailingPE": 22.019222,
  "forwardPE": 19.001152,
  "volume": 310974,
  "regularMarketVolume": 310974,
  "averageVolume": 596079,
  "averageVolume10days": 436510,
  "averageDailyVolume10Day": 436510,
  "bid": 811.55,
  "ask": 824.9,
  "bidSize": 800,
  "askSize": 800,
  "marketCap": 89543811072,
  "fiftyTwoWeekLow": 668.0,
  "fiftyTwoWeekHigh": 847.5,
  "priceToSalesTrailing12Months": 7.066942,
  "fiftyDayAverage": 791.176,
  "twoHundredDayAverage": 765.4468,
  "trailingAnnualDividendRate": 0.0,
  "trailingAnnualDividendYield": 0.0,
  "currency": "USD",
  "enterpriseValue": 81018789888,
  "profitMargins": 0.33928,
  "floatShares": 101359050,
  "sharesOutstanding": 106741000,
  "sharesShort": 1482820,
  "sharesShortPriorMonth": 1343387,
  "sharesShortPreviousMonthDate": 1690761600,
  "dateShortInterest": 1693440000,
  "sharesPercentSharesOut": 0.0137,
  "heldPercentInsiders": 0.02542,
  "heldPercentInstitutions": 0.89447,
  "shortRatio": 2.9,
  "shortPercentOfFloat": 0.0163,
  "impliedSharesOutstanding": 108559000,
  "bookValue": 225.944,
  "priceToBook": 3.6506393,
  "lastFiscalYearEnd": 1672444800,
  "nextFiscalYearEnd": 1703980800,
  "mostRecentQuarter": 1688083200,
  "earningsQuarterlyGrowth": 0.136,
  "netIncomeToCommon": 4298999808,
  "trailingEps": 37.46,
  "forwardEps": 43.41,
  "pegRatio": 4.26,
  "enterpriseToRevenue": 6.394,
  "enterpriseToEbitda": 16.826,
  "52WeekChange": 0.20008743,
  "SandP52WeekChange": 0.18466556,
  "exchange": "NMS",
  "quoteType": "EQUITY",
  "symbol": "REGN",
  "underlyingSymbol": "REGN",
  "shortName": "Regeneron Pharmaceuticals, Inc.",
  "longName": "Regeneron Pharmaceuticals, Inc.",
  "firstTradeDateEpochUtc": 670602600,
  "timeZoneFullName": "America/New_York",
  "timeZoneShortName": "EDT",
  "uuid": "e55aa808-7510-354a-9528-01782e66194d",
  "messageBoardId": "finmb_33715",
  "gmtOffSetMilliseconds": -14400000,
  "currentPrice": 824.84,
  "targetHighPrice": 1050.0,
  "targetLowPrice": 665.0,
  "targetMeanPrice": 903.9,
  "targetMedianPrice": 895.0,
  "recommendationMean": 2.1,
  "recommendationKey": "buy",
  "numberOfAnalystOpinions": 21,
  "totalCash": 8927699968,
  "totalCashPerShare": 84.256,
  "ebitda": 4815099904,
  "totalDebt": 2702200064,
  "quickRatio": 4.526,
  "currentRatio": 5.451,
  "totalRevenue": 12670799872,
  "debtToEquity": 11.251,
  "revenuePerShare": 118.474,
  "returnOnAssets": 0.09548,
  "returnOnEquity": 0.19232,
  "grossProfits": 7020000000,
  "freeCashflow": 2257374976,
  "operatingCashflow": 4738800128,
  "earningsGrowth": 0.138,
  "revenueGrowth": 0.105,
  "grossMargins": 0.53739,
  "ebitdaMargins": 0.38002,
  "operatingMargins": 0.34882,
  "financialCurrency": "USD",
  "trailingPegRatio": 1.7479
}